Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis

被引:20
|
作者
Hoedemaekers, A
Bessereau, JL
Graus, Y
Guyon, T
Changeux, JP
Berrih-Aknin, S
Vriesman, PV
De Baets, MH
机构
[1] Maastricht Univ, Dept Neurol, NL-6202 AZ Maastricht, Netherlands
[2] Univ Limburg, Dept Immunol, NL-6200 MD Maastricht, Netherlands
[3] Inst Pasteur, CNRS, UAD 1284, Unite Neurobiol Mol, F-75724 Paris, France
[4] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands
[5] Hop Marie Lannelongue, CNRS, URA 1159, F-92350 Le Plessis Robinson, France
关键词
experimental autoimmune myasthenia gravis; acetylcholine receptor; autoimmunity;
D O I
10.1016/S0165-5728(98)00126-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Injection of anti-AChR antibodies in passive transfer experimental autoimmune myasthenia gravis (EAMG) results in increased degradation of acetylcholine receptor (AChR) and increased synthesis of AChR alpha-subunit mRNA. Passive transfer of anti-Main Immunogenic Region (MIR) mAb 35 in aged rats does not induce clinical signs of disease nor AChR loss. The expression of the AChR subunit genes was analyzed in susceptible and resistant rats. In aged EAMG resistant rats, no increase in the amount of AChR alpha-subunit mRNA was measured. In vivo AChR degradation experiments did not show any increase in AChR degradation rates in aged resistant rats, in contrast to young susceptible rats. Taken together, these data demonstrate that resistance of the AChR protein to antibody-mediated degradation is the primary mechanism that accounts for the resistance to passive transfer EAMG in aged rats. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:131 / 141
页数:11
相关论文
共 50 条
  • [41] THERAPEUTIC STRATEGIES IN EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS
    DEBAETS, MH
    VRIESMAN, PJCV
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1987, 505 : 903 - 906
  • [42] Rapsyn gene therapy of experimental autoimmune myasthenia gravis
    不详
    IMMUNOBIOLOGY, 2004, 209 (4-6) : 296 - 296
  • [43] IDIOTYPES AND ANTIIDIOTYPES IN EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS
    SOUROUJON, MC
    FUCHS, S
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1986, 475 : 81 - 93
  • [44] Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil
    Janssen, Sofie P. M.
    Phernambucq, Marko
    Martinez-Martinez, Pilar
    De Baets, Marc H.
    Losen, Mario
    JOURNAL OF NEUROIMMUNOLOGY, 2008, 201 : 111 - 120
  • [46] ELECTROENCEPHALOGRAPHIC CHANGES IN EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS
    SAPHIER, D
    BIRMANNS, B
    BRENNER, T
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1993, 114 (02) : 200 - 204
  • [47] EXPERIMENTAL MYASTHENIA-GRAVIS - NEW AUTOIMMUNE MODEL
    VINCENT, A
    TRENDS IN BIOCHEMICAL SCIENCES, 1976, 1 (12) : 289 - 291
  • [48] A NEW MODEL OF EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS
    SOUAN, ML
    GEFFARD, M
    JOURNAL OF NEUROIMMUNOLOGY, 1985, 9 (06) : 327 - 338
  • [49] PERTUBATION OF THE AUTOIMMUNE IDIOTYPE NETWORK IN EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS
    VERSCHUUREN, JJ
    DEBAETS, MH
    THEUNISSEN, RD
    STORMS, P
    TZARTOS, SJ
    VRIESMAN, PJCV
    JOURNAL OF NEUROIMMUNOLOGY, 1988, 17 (03) : 263 - 263
  • [50] Respective role of thymus and muscle in autoimmune myasthenia gravis
    Moulian, N
    Wakkach, A
    Guyon, T
    Poëa, S
    Aïssaoui, A
    Levasseur, P
    Cohen-Kaminsky, S
    Berrih-Aknin, S
    MYASTHENIA GRAVIS AND RELATED DISEASES: DISORDERS OF THE NEUROMUSCULAR JUNCTION, 1998, 841 : 397 - 406